UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
More positive data for Eli Lilly’s weight loss candidate tirzepatide will boost interest in the product, as the US regulator warns of supply shortages at certain doses. 28 July 2023
French drugmaker Sanofi has reported net sales for the second quarter of 2023 of $9.9 billion euros ($10.9 billion), a 1.5% fall, with net income of 1.4 billion euros and earnings per share (EPS) of 1.15 euros. 28 July 2023
Alexion, the rare disease business of UK pharma major AstraZeneca, has entered a definitive purchase and licence agreement for a portfolio of pre-clinical gene therapy programs and enabling technologies from US pharma giant Pfizer. 28 July 2023
US House and Senate Committees this week passed legislation to control the way pharmacy benefit managers (PBMs) can profit by increasing drug price. 28 July 2023
French drugmaker Ipsen has reported a 7.2% increase in revenues in the first half of the year, driven in part by newly-acquired medicines Bylvay (odevixibat) and Tazverik (tazemetostat). 27 July 2023
Shares of US pharma major AbbVie were up 3.6% at $147.02 in early trading, after the company announced financial results for the second quarter ended June 30, 2023. 27 July 2023
In anticipation of regulatory clearance for its proposed $43 billion acquisition of Seagen, US pharma giant Pfizer today announced a reorganization of its R&D team to create a leading company in the battle against cancer. 27 July 2023
Belgium’s largest pharma company UCB has posted a downbeat set of financials for the first half of 2023, with revenues falling 11% to 2.6 billion euros ($2.9 billion). 27 July 2023
UK pharma major AstraZeneca this morning revealed that Soliris (eculizumab) has been approved in the European Union (EU) for expanded use. 27 July 2023
Swiss pharmaceutical giant Roche this morning revealed that sales for the first half of 2023 had dropped 2% to 29.78 billion Swiss francs ($33.01 billion), or -8% in franc terms. 27 July 2023
US dermatology specialist Verrica Pharmaceuticals announced the closing of the previously announced $125 million debt financing with OrbiMed, a leading healthcare investment firm. 27 July 2023
Japan’s largest pharma company Takeda today announced strong financial results for the first quarter of fiscal year 2023 (period ended June 30, 2023). The firm’s edged up 0.7% to 4,401 yen following the news. 27 July 2023
The US Food and Drug Administration (FDA) yesterday approved Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. 26 July 2023
The US Food and Drug Administration (FDA) has granted approval of Balfaxar (prothrombin complex concentrate, human-lans) for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, eg, warfarin) therapy in adult patients with need for urgent surgery or invasive procedures. 26 July 2023
Sales and profits at GSK beat expectations in the second quarter, with the firm reporting respectively a 4% and 8% increase from the same period of last year. 26 July 2023
Swiss clinical-stage biotech AC Immune today announced the appointment of Nuno Mendonca as its new chief medical officer of the neurodegenerative diseases specialist. 26 July 2023
US cell therapy developer SQZ Biotechnologies saw its shares close down almost 6% at $0.10 yesterday, after it revealed that Swiss pharma giant Roche has decided not to excercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program. 26 July 2023